drug_type
RELEVANT_DRUG
intervention_type
Antibody-based immunotherapy (polyclonal)
drug_description
An intravenous glyco-humanized polyclonal (polyspecific) antibody engineered for human-like glycosylation and multi-epitope binding to malignant T-cell surface antigens, aiming to eliminate tumor T cells via Fc-mediated effector functions (ADCC, CDC) and potential direct neutralization in PTCL subtypes.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Polyclonal
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Glyco-humanized polyspecific polyclonal antibody that binds multiple surface antigens on malignant T cells and induces their elimination via Fc-mediated effector functions (enhanced ADCC through FcγR-expressing NK cells/macrophages and complement-dependent cytotoxicity), with possible direct neutralization of target cells.
drug_name
LIS1
nct_id_drug_ref
NCT06495723